Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (392)
NICE advice (1)
Quality standard (11)
Guidance programme
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (17)
Highly specialised technologies guidance (10)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (303)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 21 to 30 of 404
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Artificial intelligence software to help detect and characterise colorectal polyps
Diagnostics guidance
TBC
Artificial intelligence technologies to aid the opportunistic detection of vertebral fragility fractures on radiographic images
Health technology evaluation
20 August 2025
Artificial intelligence technologies to help detect fractures on X-rays in urgent care
Health technology evaluation
14 January 2025
Asthma: diagnosis, monitoring and chronic asthma management
NICE guideline
27 November 2024
Asunercept for treating glioblastoma [1301]
Technology appraisal guidance
TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701
Technology appraisal guidance
TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]
Technology appraisal guidance
23 July 2025
Previous page
1
2
Current page
3
4
5
…
41
Page
3
of
41
Next page
Results per page
10
25
50
All
Back to top